In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Δ3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L.)

Cellular and Molecular Life Sciences

Volumn 66, Issue 9, 2009, Pages 1617-1629

  Zhao, G ^a,b   Zheng, X W ^a   Qin, G W ^c   Gai, Y ^a   Jiang, Z H ^a   Guo, L H ^a,b  

^a Cell Star Bio Technologies Co Limited   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

3,2 hydroxybakuchiol; Dopamine transporter; Parkinson's disease; Reuptake inhibitor; Scale up extraction

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ANTIPARKINSON AGENT; BENSERAZIDE; DELTA 3,2 HYDROXYBAKUCHIOL; FORMAZAN; LEVODOPA; PSORALEA CORYLIFOLIA EXTRACT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BINDING AFFINITY; CELL COUNT; CELL LOSS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL SHAPE; CELL TRANSPORT; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG PURITY; DRUG STRUCTURE; EXOCYTOSIS; FEMALE; HIPPOCAMPUS; HISTOPATHOLOGY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDICINAL PLANT; MONOAMINE NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NORADRENALIN UPTAKE; PARKINSON DISEASE; PLANT SEED; PSORALEA CORYLIFOLIA; RAT; ROTAROD TEST; SCALE UP; SUBSTANTIA NIGRA; SYNAPTOSOME; TREATMENT RESPONSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIPARKINSON AGENTS; CELL LINE; CHO CELLS; COCAINE; CRICETINAE; CRICETULUS; DOPAMINE; DOPAMINE AGENTS; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; NOREPINEPHRINE; PARKINSON DISEASE; PHENOLS; PSORALEA; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOSOMES; TYROSINE 3-MONOOXYGENASE;

CRICETULUS GRISEUS; CULLEN CORYLIFOLIA; MUS;

EID: 67649553164     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-009-9030-9     Document Type: Article

References (38)

1. Hsieh, M. T., Peng,W. H.,Wu, C. R., andWang,W. H. (2000) The ameliorating effects of the cognitive-enhancing Chinese herbs on scopolamine-induced amnesia in rats. Phytother. Res. 14, 375-377.
2. Choi, Y. H., Yon, G. H., Hong, K. S., Yoo, D. S., Choi, C. W., Park, W. K., Kong, J. Y., Kim, Y/S., and Ryu, S. Y. (2008) In vitro BACE-1 inhibitory phenolic components from the seeds of Psoralea corylifolia. Planta Med. 74,1405-1408.
3. Chen,Y.,Wang, H.D.,Xia, X.,Kung,H. F., Pan,Y., andKong, L. D. (2007) Behavioral and biochemical studies of total furocoumarins from seeds of Psoralea corylifolia in the chronic mild stress model of depression in mice. Phytomedicine 14, 523-529.
4. Chen, Y., Kong, L. D., Xia, X., Kung, H. F., and Zhang, L. (2005) Behavioral and biochemical studies of total furocoumarins from seeds of Psoralea corylifolia in the forced swimming test in mice. J. Ethnopharmacol. 96, 451-459.
5. Xu,Q., Pan, Y., Yi, L. T., Li, Y. C.,Mo, S. F., Jiang, F. X., Qiao, C. F., Xu, H. X., Lu, X. B., Kong, L. D., and Kung, H. F. (2008) Antidepressant-like effects of psoralen isolated from the seeds of Psoralea corylifolia in the mouse forced swimming test. Biol. Pharm. Bull. 31,1109-1114.
6. Wang, H. M.,Wu, D. Y., Liu, X. H., and Meng, X. Z. (2007) A 30-case report on Parkinson disease treatment with Zi-Shen-Yang-Gan-Xi-Feng cocktail combining with madopar. Shaanxi J. Tradit. Chin. Med. 28, 668-669.
7. Hu,Y.Y.(2008)Aclinic study on cocktail Parkinson treatment. Liaoning J. Tradit. Chin. Med. 35, 65-67.
8. Zhao, G., Li, S., Qin, G. W., Fei, J., and Guo, L. H. (2007) Inhibitive effects of Fructus Psoraleae extract on dopamine transporter and noradrenaline transporter. J. Ethnopharmacol. 112, 498-506.
9. Zhao,G., Zang, S. Y., Zheng, X.W., Zhang, X.H., and Guo, L. H. (2008) Bakuchiol analogs inhibit monoamine transporters and regulate monoaminergic functions. Biochem. Pharmacol. 75,1835-1847.
10. Hersch, S. M., Yi, H., Heilman, C. J., Edwards, R. H., and Levey, A. I. (1997) Subcellular locallization and molecular topology of dopamine transporter in the striatum and substantia nigra. J. Comp. Neurol. 388, 211-227.
11. Nelson, N. (1998) The family of Na+/Cl- neurotransmitter transporters. J. Neurochem. 71,1785-1793.
12. Bannon, M. J. (2005) The dopamine transporter: role in neurotoxicity and human disease. Toxicol. Appl. Pharmacol. 204, 355-360.
13. Uhl, G. R. (1998) Hypothesis: the role of dopamine transporters in selective vulnerability of cells on Parkinson's disease. Ann. Neurol. 43, 555-560.
14. Hansard, M. J., Smith, L. A., Jackson, M. J., Cheetham, S. C., and Jenner, P. (2002) Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. Eur. J. Pharmacol. 451, 157-160.
15. Hansard, M. J., Smith, L. A., Jackson, M. J., Cheetham, S. C., and Jenner, P. (2002). Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl -1,2,3,6- tetrahydropyridine- treated primates. J Pharmacol. Exp. Ther. 303, 952-958.
16. Yao, S. T. and Yang, B. (1995) hydroxybakuchiol content measurement in fructus psoraleae. Zhong GuoZhongYaoZha Zhi 20, 681-683.
17. Labbe,C., Faini, F.,Coll, J., and Conolly, J.D. (1996) Bakuchiol derivatives from the leaves of Psoralea glandulosa. Phytochemistry 42: 1299-1303.
18. Matsuda, H., Sugimoto, S., Morikawa, T., Matsuhira, K., Mizuguchi, E., Nakamura, S., and Yoshikawa, M. (2007) Bioactive constituents from Chinese natural medicines: XX. inhibitors of antigen-induced degranulation in RBL-2H3 cells from the seeds of Psoralea corylifolia. Chem. Pharm. Bull. (Tokyo) 55, 106-110.
19. Kawai, H.,Makino, Y., Hirobe,M., and Ohta, S. (1998) Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism. J. Neurochem. 70,745-751.
20. Storch, A., Hwang, Y. I., Gearhart, D. A., Beach, J. W., Neafsey, E. J., Collins,M.A., and Schwarz, J. (2004) Dopamine transporter-mediated cytotoxicity of b-carbolinium derivatives related to Parkinson's disease: relationship to transporterdependent uptake. J Neurochem 89: 685-694.
21. Cassarino,D. S., Parks, J. K., Parker, Jr.W.D., and Bennett, Jr. J. P. (1999) The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Acta. Biochim. Biophys. Sin. 1453, 49-62.
22. Vila, M., Vukosavic, S., Jackson-Lewis, V., Neystat, M., Jakowec, M., and Przedborski, S. (2000) a-Synuclein upregulation in substantia nigra dopaminergic neurons following administration of parkinsonian toxin MPTP. J. Neurochem. 74, 721-729.
23. Isobe, I., Michikawa, M., and Yanagisawa, K. (1999) Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid betaprotein and chloroquine in cultured rat astrocytes Neurosci. Lett. 266,129-132.
24. Ishiyama, M.,Miyazono, Y., and Sasamoto, K. (1997)Ahighly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 44,1299-1305.
25. Shearman, M. S., Hawtin, S. R., and Tailor, V. J. (1995) The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by b-amyloid peptides. J. Neurochem. 65, 218-227.
26. Shearman, M. S., Ragan, C. I., and Iversen, L. L. (1994) Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of b-amyloid-mediated cell death. Proc. Natl. Acad. Sci. USA 91,1470-1474.
27. Ding, J., Shi, J., Cui, D., Xu, L., Duan, S., Guo, L., and Fei, J. (2006) Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J. Med. Chem. 49, 4048-4051.
28. Torres, G. E. (2006) The dopamine transporter proteome. J. Neurochem. 97 Suppll, 3-10.
29. Ohashi, S., Mori, A., Kurihara, N., Mitsumoto, Y., and Nakai, M. (2006) Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Neurosci. Lett. 401, 183-187.
30. Watanabe,Y., Himeda, T., and Araki, T. (2005) Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Med. Sci. Monit. 11, 17-23.
31. Semkova, I. and Krieglstein, J. (1999) Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain. Res. Brain Res. Rev. 30, 176-188.
32. Aloyz, R., Fawcett, J. P., Kaplan, D. R., Murphy, R. A., and Miller, F. D. (1999) Activity-dependent activation of TrkB neurotrophin receptors in the adult CNS. Lang. Learn. 6, 216-231.
33. Troadec, J. D., Marien, M., Darios, F., Hartmann, A., Ruberg, M., Colpaert, F., and Michel, P. P. (2001) Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J. Neurochem. 79, 200-210.
34. Archer, T. and Fredriksson, A. (2006) Influence of noradrenaline denervation on MPTP-induced deficits in mice. J. Neural. Transm. 113, 1119-1129.
35. Rommelfanger, K. S., Weinshenker, D., and Miller, G. W. (2004) Reduced MPTP toxicity in noradrenaline transporter knockout mice. J. Neurochem. 91, 1116-1124.
36. Haraguchi, H., Inoue, J., Tamura, Y., and Mizutani, K. (2002) Antioxidative components of Psoralea corylifolia (Leguminosae). Phytother. Res. 16, 539-544.
37. Pearce, R. K., Smith, L. A., Jackson, M. J., Banerji, T., Scheel-Krüger, J., and Jenner, P. (2002) The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov. Disord. 17, 877-886.
38. Nutt, J.G., Carter, J.H., and Sexton,G. J. (2004) The dopamine transporter: importance in Parkinson's disease. Ann. Neurol. 55, 766-773.